drugset / Trial / NCT02228655

An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD

NCT02228655 ↗

Phase 0 Terminated 2 enrolled FerruMax Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.

Timeline

Start
2014-10
Primary completion
2015-04
Completion
2015-07

Outcome

Outcome not reported

Stopped (Enrollment): “Inability to recruit patients meeting eligibilty criteria.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FMX-8 Protein / enzyme biologic 15 mg/kg Other